Measuring tumor pharmacodynamic response using PET proliferation probes: the case for 2-[(11)C]-thymidine.Citation formats

  • Authors:
  • P Wells
  • CML West
  • T Jones
  • A Harris
  • PM. Price

Standard

Measuring tumor pharmacodynamic response using PET proliferation probes: the case for 2-[(11)C]-thymidine. / Wells, P; West, CML; Jones, T; Harris, A; Price, PM.

In: Biochimica et biophysica acta, Vol. 1705( 2), 17.12.2004.

Research output: Contribution to journalArticle

Harvard

Wells, P, West, CML, Jones, T, Harris, A & Price, PM 2004, 'Measuring tumor pharmacodynamic response using PET proliferation probes: the case for 2-[(11)C]-thymidine.', Biochimica et biophysica acta, vol. 1705( 2).

APA

Wells, P., West, CML., Jones, T., Harris, A., & Price, PM. (2004). Measuring tumor pharmacodynamic response using PET proliferation probes: the case for 2-[(11)C]-thymidine. Biochimica et biophysica acta, 1705( 2).

Vancouver

Wells P, West CML, Jones T, Harris A, Price PM. Measuring tumor pharmacodynamic response using PET proliferation probes: the case for 2-[(11)C]-thymidine. Biochimica et biophysica acta. 2004 Dec 17;1705( 2).

Author

Wells, P ; West, CML ; Jones, T ; Harris, A ; Price, PM. / Measuring tumor pharmacodynamic response using PET proliferation probes: the case for 2-[(11)C]-thymidine. In: Biochimica et biophysica acta. 2004 ; Vol. 1705( 2).

Bibtex

@article{593b6aef6ad045fcb6be18a8f70fdd55,
title = "Measuring tumor pharmacodynamic response using PET proliferation probes: the case for 2-[(11)C]-thymidine.",
abstract = "[(18)F]-fluorodeoxyglucose ((18)F-FDG) positron emission tomography (PET) is becoming accepted as a diagnostic tool for cancer, but the potential uses of PET in oncology extend beyond the imaging of glucose metabolism. The development of a PET proliferation probe would be a useful pharmacodynamic tool. [(11)C]-thymidine PET has been assessed in man as a specific measure of tumor proliferation. Uptake of [(11)C]-thymidine is related to DNA synthesis and, in human tumors, correlates with proliferation. When compared with (18)F-FDG, it has been shown to be a more sensitive discriminator of early clinical tumor response. 2-[(11)C]-thymidine PET scanning of patients enrolled in early phase clinical trials is feasible and should support future drug development. Although recent research is moving away from the validation of thymidine towards thymidine analogues radiolabeled with (18)F, the better specificity of thymidine for DNA should be the rationale for its continued development and application as a PET probe. This review describes the historical development, application and current research status of [(11)C]-thymidine PET, and aims to highlight the need for its continuing development as a marker of tumor proliferation.",
keywords = "diagnostic use: Carbon Radioisotopes, Cell Proliferation, Clinical Trials, Comparative Study, DNA Probes, diagnostic use: Fluorodeoxyglucose F18, Humans, drug therapy: Neoplasms, methods: Positron-Emission Tomography, Reproducibility of Results, Research Support, Non-U.S. Gov't, chemistry: Thymidine",
author = "P Wells and CML West and T Jones and A Harris and PM. Price",
year = "2004",
month = "12",
day = "17",
language = "English",
volume = "1705( 2)",
journal = "Biochimica et biophysica acta",
issn = "0006-3002",
publisher = "Elsevier BV",

}

RIS

TY - JOUR

T1 - Measuring tumor pharmacodynamic response using PET proliferation probes: the case for 2-[(11)C]-thymidine.

AU - Wells, P

AU - West, CML

AU - Jones, T

AU - Harris, A

AU - Price, PM.

PY - 2004/12/17

Y1 - 2004/12/17

N2 - [(18)F]-fluorodeoxyglucose ((18)F-FDG) positron emission tomography (PET) is becoming accepted as a diagnostic tool for cancer, but the potential uses of PET in oncology extend beyond the imaging of glucose metabolism. The development of a PET proliferation probe would be a useful pharmacodynamic tool. [(11)C]-thymidine PET has been assessed in man as a specific measure of tumor proliferation. Uptake of [(11)C]-thymidine is related to DNA synthesis and, in human tumors, correlates with proliferation. When compared with (18)F-FDG, it has been shown to be a more sensitive discriminator of early clinical tumor response. 2-[(11)C]-thymidine PET scanning of patients enrolled in early phase clinical trials is feasible and should support future drug development. Although recent research is moving away from the validation of thymidine towards thymidine analogues radiolabeled with (18)F, the better specificity of thymidine for DNA should be the rationale for its continued development and application as a PET probe. This review describes the historical development, application and current research status of [(11)C]-thymidine PET, and aims to highlight the need for its continuing development as a marker of tumor proliferation.

AB - [(18)F]-fluorodeoxyglucose ((18)F-FDG) positron emission tomography (PET) is becoming accepted as a diagnostic tool for cancer, but the potential uses of PET in oncology extend beyond the imaging of glucose metabolism. The development of a PET proliferation probe would be a useful pharmacodynamic tool. [(11)C]-thymidine PET has been assessed in man as a specific measure of tumor proliferation. Uptake of [(11)C]-thymidine is related to DNA synthesis and, in human tumors, correlates with proliferation. When compared with (18)F-FDG, it has been shown to be a more sensitive discriminator of early clinical tumor response. 2-[(11)C]-thymidine PET scanning of patients enrolled in early phase clinical trials is feasible and should support future drug development. Although recent research is moving away from the validation of thymidine towards thymidine analogues radiolabeled with (18)F, the better specificity of thymidine for DNA should be the rationale for its continued development and application as a PET probe. This review describes the historical development, application and current research status of [(11)C]-thymidine PET, and aims to highlight the need for its continuing development as a marker of tumor proliferation.

KW - diagnostic use: Carbon Radioisotopes

KW - Cell Proliferation

KW - Clinical Trials

KW - Comparative Study

KW - DNA Probes

KW - diagnostic use: Fluorodeoxyglucose F18

KW - Humans

KW - drug therapy: Neoplasms

KW - methods: Positron-Emission Tomography

KW - Reproducibility of Results

KW - Research Support, Non-U.S. Gov't

KW - chemistry: Thymidine

M3 - Article

VL - 1705( 2)

JO - Biochimica et biophysica acta

JF - Biochimica et biophysica acta

SN - 0006-3002

ER -